Arca
Skip to content
Tools
Tools

Breast cancer triple negative

Drug research and approvals for breast cancer triple negative: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 353 studies of breast cancer triple negative are recruiting on ClinicalTrials.gov, and Health Canada has authorized 31 drug trials for it since 2013.

  • Recruiting worldwide: 353
  • Trials authorized in Canada: 31
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 353 recruiting on ClinicalTrials.gov ↗

How its trials ended

920 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 216 whose ending is known, 24% met their primary endpoint, 7% missed it and 69% stopped early.

  • Ongoing44949%
  • Completed, result not reported15617%
  • Status unknown9911%
  • Stopped: other or unclear738%
  • Met its primary endpoint526%
  • Stopped: sponsor or business decision354%
  • Stopped: enrollment or feasibility192%
  • Stopped: lack of efficacy162%
  • Missed its primary endpoint152%
  • Stopped: funding51%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 31; search them all in Canada trials
Jul 27, 2026Shorter anthracycline-free chemo immunotherapy adapted to pathological response in early triple negative breast cancer (SCARLET), a randomized phase III studyCarboplatin / Pembrolizumab (keytruda)BC Cancer, Part of The Provincial Health Services AuthorityPending
Dec 17, 2025Rebooting sensitivity to checkpoint blockade therapy in triple-negative breast cancer with isunakinra (resett- i)IsunakinraUniversity Health NetworkOngoing
Nov 13, 2025Fmt in triple negative breast cancer guided by ctdna (FRIDA)Fecal transplantation / Fecal microbial therapyDr. Mark BasikPending
Oct 15, 2025A phase II study of first-line sacituzumab govitecan in advanced untreated triple negative breast cancer patientTrodelvy (sacituzumab govitecan)BC CancerOngoing
Jul 10, 2025Determine whether administering celecoxib during radiotherapy can reduce the risk of recurrence of triple-negative breast cancer. pilot studyCelecoxibCiusss De L'Estrie - Centre Hospitalier Universitaire De SherbrookePending
Mar 19, 2025A phase 2, umbrella study to evaluate the safety, tolerability, and clinical activity of investigational agents for newly diagnosed, high-risk, earlystage…MK-5890 / Keytruda / Abraxane / Carboplatin / Doxorubicin / Epirubicin /…Merck & Co. (MSD)Pending
Mar 27, 2024Optimice-pcr: de-escalation of therapy in early-stage TNBC patients who achieve pcr after neoadjuvant chemotherapy with checkpoint inhibitor therapyKeytrudaCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityOngoing
Jan 17, 2024Il-1 inhibition for patients with early stage triple negative and er-low breast cancer: a window-of-opportunity studyAnakinraPrincess Margaret Cancer CentrePending
Nov 16, 2023Efficacy of intralesional IL-2 for resectable triple negative breast cancerProleukinDr. Gregory Christopher Knapp, Qe Ii Health Sciences Centre, Nova Scotia HealthPending
Sep 22, 2023A phase III, open-label, randomised study of neoadjuvant datopotamab deruxtecan (dato-dxd) plus durvalumab followed by adjuvant durvalumab with or without…Datopotamab deruxtecan (dato DXD/DS-1062A) / Imfinzi / KeytrudaAstraZeneca PharmaceuticalsOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.